Seattle-based Mirador Biomedical, the developer of a device to prevent dangerous bleeding episodes in hospitals, said today it has gotten clearance from regulators to start selling the product in the European Union. The company won FDA approval last October, and since then, its device has been used in more than 2,000 procedures in more than 50 U.S. hospitals, who are looking to avoid mistaken insertions of catheters into the wrong kind of blood vessel.”With U.S. sales picking up briskly, we look forward to expanding our commercialization effort in the EU,” said Mirador CEO Karl Schmidt, in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
